icon-folder.gif   Conference Reports for NATAP  
 
  8th International Congress on
Drug Therapy in HIV Infection
November 12-16, 2006
Glasgow, Scotland
Back grey_arrow_rt.gif
 
 
 
Tipranavir 500/100 & 500/200 vs Kaletra in Naives
 
 
  Reported by Jules Levin
8th Intl Congress on Drug Therapy in HIV
Glasgow, UK, Nov 16, 2006
 
"Efficacy and safety of two doses of tipranavir/r versus lopinavir/r based therapy in antiretroviral na´ve patients: results of BI1182.33 trial"
 
David Cooper on behalf of the BI1182.33 investigators
 
AUTHOR CONCLUSIONS
Post-hoc efficacy analysis performed after all patients had completed Week 60 visit: the 500 mg/200 mg BID dose was non-inferior to LPV/r. However, the 500 mg/100 mg BID dose was not non-inferior.
 
The two TPV/r doses tested were effective in treatment na´ve patients: -- Similar percentage of patients reaching VL <50 copies/mL at Week 48 in both arms
-- Similar increase in CD4+ cells in both arms
 
Increased rate of Grade 3/4 ALT/AST levels in patients receiving 500 mg/200 mg BID compared with other arms; dose not suitable for HIV treatment na´ve patients with WT virus .
 
Grade 3/4 lipid elevations and transaminase elevations in TPV/r 500 mg/100 mg BID were comparable to those in LPV/r recipients.
 
Trial design
 
Open-label, randomized, international, parallel group, non-inferiority trial. Primary Endpoint: percentage of treatment responders (VL <50 cp/ml) at week 48.
 

DoseEs-1.gif

Demographic Baseline Data
Average CD4 was about 200 and viral load about 100,000 c/ml About 50% had >100,000 c/ml.

TPV-2.gif

Results: Week 48 analysis
 
Disposition at Week 48

*3 patients randomized to receive TPV/r-100 received TPV/2-200.

week48-3.gif

15 patients in all three arms had their first VL <50 copies/mL at Week 48. First opportunity for these patients to have confirmed VL <50 copies/mL was at Week 60.
 
For this reason, a Week 48 analysis including Week 60 data from all patients was conducted.
 

DetailedReas-4.gif

adverse2-1.gif

grade34-1.gif